Advertisement
Screener

Coya Therapeutics, Inc. (COYA) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price

2.0 / 5 stars · 13/32 Roast Me

Coya Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price

Coya Therapeutics, Inc. (COYA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $1.09 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-11

  • Coya Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.09, a 0.93% increase year-over-year.
  • Coya Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.08.
  • Coya Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $1.08, a 0.00% change from fiscal 2024.
  • Coya Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $1.08, a 7.69% decline from fiscal 2023.
  • Coya Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $1.17, a 8.33% increase from fiscal 2022.
  • Coya Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $1.08.
Period endShare-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 monthShare-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month
2026-06-30$1.09
10-Q · filed 2026-08-11
2025-12-31$1.08
10-K · filed 2026-03-16
2025-09-30$1.09
10-Q · filed 2025-11-12
2025-06-30$1.09
10-Q · filed 2025-08-12
2025-03-31$1.09
10-Q · filed 2025-05-13
2024-12-31$1.08
10-K · filed 2025-03-18
2024-09-30$1.08
10-Q · filed 2024-11-06
2024-06-30$1.08
10-Q · filed 2024-08-12
2024-03-31$1.08
10-Q · filed 2024-05-09
2023-12-31$1.17
10-K · filed 2024-03-19
2022-12-31$1.08
10-K · filed 2023-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95
Aardvark Therapeutics, Inc. (AARD)United States$0.121B-1.80
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
INOVIO PHARMACEUTICALS, INC. (INO)United States$0.125B-1.35
IMMUNIC, INC. (IMUX)United States$0.127B-1.88
Immuneering Corp (IMRX)United States$0.113B-12.51
Quantum Cyber N.V. (QUCY)$0.113B
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
MEDICINOVA INC (MNOV)United States$0.130B-6.04
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31